Company / R&D Expense
Adaptive Biotechnologies Corp R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$93.8M
FY2025
5-year range
$93.8M / $142.3M
FY2021-FY2025
Trend
-8.9%
vs FY2024
Sector context
#148 of 210
Health Care
What the data says
At $94M, Adaptive Biotechnologies Corp's r&d expense ranks #148 of 210 in the Health Care sector. R&D Expense has declined for 4 consecutive years, from $142M in FY2021 to $94M in FY2025.
Based on SEC 10-K filings.
$94M in FY2025 with a 5-year CAGR of -4.2%.
Declined from $122M to $94M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -12.9%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Sector benchmark
#148 of 210 in Health CareTop 70% of 210This company $93.8M Sector average $644.0M
▼
-85.4% below sector average
Key checks
Key Insights
- Adaptive Biotechnologies Corp's r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 8.9% year-over-year.
- Ranks #148 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $93.8M | -8.9% |
| FY2024 | $103.0M | -15.7% |
| FY2023 | $122.1M | -13.9% |
| FY2022 | $141.8M | -0.4% |
| FY2021 | $142.3M | +22.6% |
| FY2020 | $116.1M | +64.2% |
| FY2019 | $70.7M | +80.6% |
| FY2018 | $39.2M | +22.4% |
| FY2017 | $32.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026